US FDA Seeking More ‘Open Access’ To Real World Data From Payers

Agency is paying “enormous sums” to access postmarket information from payers, Commissioner Gottlieb says, suggesting public-private partnerships to enhance access.

Big data analytics and business intelligence (BI) concept with chart and graph icons on a digital screen interface

FDA is hoping payers will “do more” to share data on real-world outcomes of drugs, including cancer drugs, Commissioner Scott Gottlieb says.

The agency needs “help from industry, especially the payers, who sit on mountains of data that can inform the sort...

More from Drug Safety

More from Pink Sheet